<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444728</url>
  </required_header>
  <id_info>
    <org_study_id>CSTAR001</org_study_id>
    <nct_id>NCT02444728</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE</brief_title>
  <acronym>CHORUS</acronym>
  <official_title>Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese SLE Treatment And Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese SLE Treatment And Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treating severe thrombocytopenia is a challenge in the management of systemic lupus
      erythematosus. Although rheumatologists have followed some rules in real practice,there is
      very few evidence to support the current treatment algorithm. The purpose of this study is to
      compare the complete remission rate and partial remission rate of cyclophosphamide and
      hydroxychloroquine for treating severe thrombocytopenia in Chinese SLE patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective,randomized,open-label,multi-center clinical trial. The aim of this
      study is to test the efficacy of GC(gluco-corticosteroid)+HCQ(hydroxychloroquine) and
      GC(glucocorticosteroid)+CTX(cyclophosphamide) with sequential AZA(azathioprine) in the
      induction and maintenance therapy of severe thrombocytopenia in SLE patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>at 12 month</time_frame>
    <description>percentage of patients whose platelet count &gt; 100X109/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>partial remission rate</measure>
    <time_frame>at 12 month</time_frame>
    <description>percentage of patients whose platelet increase to &gt;30X109/L or with at least a two folds increase of the baseline(ie, pretreatment) count and the absence of bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Group1:Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide, Azathioprine &amp; Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.
Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine 200 mg BID for 12 months</description>
    <arm_group_label>Group1:Hydroxychloroquine</arm_group_label>
    <arm_group_label>Group 2:Cyclophosphamide</arm_group_label>
    <other_name>Fenle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 1000mg intravenous infusion every month for 6 months</description>
    <arm_group_label>Group 2:Cyclophosphamide</arm_group_label>
    <other_name>Huanlinxianan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months</description>
    <arm_group_label>Group 2:Cyclophosphamide</arm_group_label>
    <other_name>liuzuopiaolin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months</description>
    <arm_group_label>Group1:Hydroxychloroquine</arm_group_label>
    <arm_group_label>Group 2:Cyclophosphamide</arm_group_label>
    <other_name>meizhuole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients fulfilled the 1997 ACR modified or SLICC classification criteria of SLE；

          2. New onset thrombocytopenia: platelet count &lt;30X109/L(by both routine test and citric
             acid anti-coagulated blood count test) within 3 months

        Exclusion Criteria:

          1. Thrombocytopenia caused by other reasons, including drugs；

          2. Positive for active HAV(hepatitis A virus)/HBV(hepatitis B virus) infection

          3. Active HIV(human immunodeficiency virus) or HCV(hepatitis C virus) infection;

          4. Active HP(Helicopter pylori) infection;

          5. Severe liver and kidney dysfunction；

          6. Severe neuropsychiatric lupus；

          7. No response to high dose steroid and/or cyclophosphamide 1 month prior to study
             enrollment；

          8. Uncontrolled diabetes or hypertension before entry

          9. Active GI bleeding 3 months before entry

         10. Intolerant to HCQ in the past treatment history；

         11. Severe bone marrow suppression or liver damage caused by cyclophosphamide in the past
             history；

         12. Active infection , including bacteria, virus, fungi, mycobacteria

         13. Allergy to any of the study medications

         14. Confirmed TTP(thrombolic thrombocytopenic purpura)or CAPS(catastrophic
             anti-phosphilipid syndrome)

         15. Platelet count less than 20X109/L with active bleeding

         16. Myelodysplastic diseases

         17. Patients with heart and lung function impairment

         18. thiopurine S-methyltransferase (TPMT) gene positive -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofeng Zeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese SLE Treatment And Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaofeng Zeng, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinping Tian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinping Tian, MD</last_name>
    <phone>86-10-69158793</phone>
    <email>tianxp6@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mengtao Li, MD</last_name>
    <phone>86-10-69158793</phone>
    <email>mengtao.li@cstar.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the Affiliated Hospital to Bangbu Medical University</name>
      <address>
        <city>Bangbu</city>
        <state>Anhui</state>
        <zip>233000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhijun Li, MD</last_name>
      <phone>13955289810</phone>
      <email>zhijun.li@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Changhao Xie, MD</last_name>
      <phone>15255227208</phone>
      <email>uglboy2002@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hebei Provincial Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengxiao Zhang, MD</last_name>
      <phone>13722879168</phone>
      <email>fengxiao.zhang@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wei Lin, MD</last_name>
      <phone>17736909239</phone>
      <email>linwei272@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Xiangya Medical University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxia Zuo, MD</last_name>
      <phone>86-13787216257</phone>
      <email>xiaoxia.zuo@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>jing Huang, MD</last_name>
      <phone>15874869645</phone>
      <email>jilianhj@csu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Huhehaote</city>
        <state>Inner Mongolia</state>
        <zip>010050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongbin Li, MD</last_name>
      <phone>13948536552</phone>
      <email>hongbin.li@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ning Tie, MD</last_name>
      <phone>13948610720</phone>
      <email>tieting@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sino-Japanese Friendship Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liqi Bi, MD</last_name>
      <phone>13578879099</phone>
      <email>liqi.bi@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Cuili Ma, MD</last_name>
      <phone>13664438195</phone>
      <email>macuili@yeah.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Xian Communication Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lan He, MD</last_name>
      <phone>13809156236</phone>
      <email>lan.he@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Bomiao Ju, MD</last_name>
      <phone>18792778105</phone>
      <email>18792778105@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Zhu, MD</last_name>
      <phone>13700235112</phone>
      <email>ping.zhu@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Weitong Chen, MD</last_name>
      <phone>15771943030</phone>
      <email>chenweitong0818@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xinjiang Provincial Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijun Wu, MD</last_name>
      <phone>13999265917</phone>
      <email>lijun.wu@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Cainan Luo, MD</last_name>
      <phone>15739551667</phone>
      <email>future_tense@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Xu, MD</last_name>
      <phone>13888566797</phone>
      <email>jian.xu@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Shu Li, MD</last_name>
      <phone>15198785584</phone>
      <email>gglis@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijng Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cibo Huang, MD</last_name>
      <phone>86-10-86372388</phone>
      <email>cibo.huang@cstar.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zheng, MD</last_name>
      <phone>13911170090</phone>
      <email>yi.zheng@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yongfeng Zhang, MD</last_name>
      <phone>13671239495</phone>
      <email>zyf760116@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaochun Wang, MD</last_name>
      <phone>13910729602</phone>
      <email>guochun.wang@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Li Ma, MD</last_name>
      <phone>13910289103</phone>
      <email>marryma@vip.sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinping Tian, MD</last_name>
      <phone>86-13691165939</phone>
      <email>tianxp6@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Ai Xu, Coordinator</last_name>
      <phone>86-15910602883</phone>
      <email>1989xuai@sina.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Mengtao Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxia Li, MD</last_name>
      <phone>13501164945</phone>
      <email>xiaoxia.li@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yi Zhao, MD</last_name>
      <phone>13811038669</phone>
      <email>zhaoyi_peking@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>General Hospital of Tianjing Medical University</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wei, MD</last_name>
      <phone>13920182411</phone>
      <email>wei.wei@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Na Zhang, MD</last_name>
      <phone>13820489562</phone>
      <email>lunazhang22@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus. 2001;10(3):152-3. Review.</citation>
    <PMID>11315344</PMID>
  </reference>
  <reference>
    <citation>Blasco LM. Hydroxychloroquine alone for severe immune thrombocytopenic purpura associated with systemic lupus erythematosus. Lupus. 2013 Jun;22(7):752-3. doi: 10.1177/0961203313490239. Epub 2013 May 22.</citation>
    <PMID>23698017</PMID>
  </reference>
  <reference>
    <citation>Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003 Aug 28;349(9):831-6.</citation>
    <PMID>12944568</PMID>
  </reference>
  <results_reference>
    <citation>Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus. 2005;14 Suppl 1:s33-8.</citation>
    <PMID>15803929</PMID>
  </results_reference>
  <results_reference>
    <citation>Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984. Epub 2011 Feb 16. Review.</citation>
    <PMID>21325604</PMID>
  </results_reference>
  <results_reference>
    <citation>Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1990 May 1;112(9):674-7.</citation>
    <PMID>2334081</PMID>
  </results_reference>
  <results_reference>
    <citation>Roach BA, Hutchinson GJ. Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide. Arthritis Rheum. 1993 May;36(5):682-4.</citation>
    <PMID>8489547</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine AB, Erkan D. Clinical assessment and management of cytopenias in lupus patients. Curr Rheumatol Rep. 2011 Aug;13(4):291-9. doi: 10.1007/s11926-011-0179-5. Review.</citation>
    <PMID>21503695</PMID>
  </results_reference>
  <results_reference>
    <citation>Khellaf M, Chabrol A, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, Bierling P, Michel M, Godeau B. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014 Feb;89(2):194-8. doi: 10.1002/ajh.23609. Epub 2013 Nov 20.</citation>
    <PMID>24254965</PMID>
  </results_reference>
  <results_reference>
    <citation>Arnal C, Piette JC, Léone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002 Jan;29(1):75-83.</citation>
    <PMID>11824975</PMID>
  </results_reference>
  <results_reference>
    <citation>Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmun Rev. 2013 May;12(7):784-91. doi: 10.1016/j.autrev.2013.02.001. Epub 2013 Feb 24. Review.</citation>
    <PMID>23462431</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thrombocytopenia</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

